ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
ALX Oncology Holdings reported a net loss of $14.2 million for Q1 2021, worsening from the prior year's loss of $7.4 million. Cash and cash equivalents totaled $429.9 million, sufficient to fund operations through 2024. Significant progress was made with the initiation of the Phase 2 ASPEN-03 study evaluating ALX148 in combination with KEYTRUDA for HNSCC. The company also strengthened its IP portfolio with a U.S. patent covering ALX148, set to expire in 2036. R&D expenses surged to $9.8 million, primarily due to increased clinical costs related to ALX148.
- Initiated Phase 2 ASPEN-03 study for ALX148 with KEYTRUDA.
- Strengthened IP portfolio with U.S. patent valid until at least 2036.
- Sufficient cash reserves of $429.9 million to fund operations through 2024.
- Increased net loss to $14.2 million in Q1 2021 from $7.4 million in Q1 2020.
- R&D expenses rose to $9.8 million, up from $3.8 million in Q1 2020.
- No related-party revenue in Q1 2021 compared to $0.7 million in Q1 2020 due to terminated agreement.
BURLINGAME, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2021 and provided recent clinical development and operational highlights.
"Having achieved important milestones in the first quarter of 2021, we look forward to what we expect will be another exciting year of substantial progress for our lead candidate, ALX148, as we prepare to initiate several clinical trials in combination with other agents in a variety of indications, as well as multiple anticipated data readouts during the year,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology.
“We recently dosed the first patient in our Phase 2 study (ASPEN-03) to evaluate ALX148 in combination with KEYTRUDA® in first line treatment of patients with PD-L1 expressing metastatic or unresectable, recurrent head and neck squamous cell carcinoma (“HNSCC”) and we are preparing to initiate a second Phase 2 study (ASPEN-04) in the coming weeks with ALX148 in combination with KEYTRUDA and standard chemotherapy in a similar patient population but regardless of PD-L1 expression status. We also look forward to presenting additional results from a Phase 1b study (ASPEN-01) of ALX148 in combination with trastuzumab, ramucirumab and paclitaxel in patients with HER2-positive gastric/gastroesophageal junction cancer (“G/GEJ”) at the upcoming ESMO 23rd World Congress on Gastrointestinal Cancer in July,” Dr. Pons continued.
Recent Clinical Developments for ALX148:
- Phase 2 ASPEN-03 study
In May 2021, dosed first patient in the Phase 2 ASPEN-03 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with HNSCC.
- Strengthened IP Portfolio Covering ALX148
In April 2021, ALX Oncology announced that the post-grant review period for granted U.S. Patent No. 10,696,730 ended on March 30, 2021. This patent covers the lead product candidate ALX148, a next generation CD47-blocking therapeutic that combines a high-affinity signal regulatory protein-alpha (“SIRPα”) CD47-binding domain fused with an inactivated, proprietary Fc domain. The U.S. patent is not expected to expire before August 5, 2036, excluding patent term adjustments or extensions.
Recent Operational Highlights:
- In May 2021, reported the appointment of Shelly Pinto as VP Finance and Chief Accounting Officer. Ms. Pinto was most recently VP of Finance and Operations at Tizona Therapeutics and is a Certified Public Accountant.
First Quarter 2021 Financial Results:
- Cash and Cash Equivalents: Cash and cash equivalents as of March 31, 2021 were
$429.9 million . ALX Oncology believes its cash and cash equivalents is sufficient to fund planned operations through 2024. - Net loss: Generally accepted accounting principles (GAAP) net loss attributable to common stockholders was
$14.2 million , or$0.35 per basic and diluted share and$7.4 million , or$2.37 per basic and diluted share for the three months ended March 31, 2021, and 2020, respectively. Non-GAAP net loss attributable to common stockholders was$12.4 million for the three months ended March 31, 2021, as compared to$7.1 million for the three months ended March 31, 2020. A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release. - Related-party Revenue: There was no related-party revenue for the three months ended March 31, 2021, compared to
$0.7 million for the same prior-year period. The decrease in related-party revenue relates to the termination of the research and development agreement with Tallac Therapeutics, Inc. in July 2020. - Research and Development (“R&D”) Expenses: R&D expenses consist primarily of pre-clinical, clinical and manufacturing expenses related to the development of ALX148. These expenses for the three months ended March 31, 2021, were
$9.8 million , compared to$3.8 million for the same prior-year period. The increase of$6.0 million was primarily attributable to an increase of$5.1 million in clinical and development costs due to higher expenses associated with increased pre-clinical, clinical and other research costs in advancement of our current lead product candidate, ALX148, as well as an increase of$0.5 million in stock-based compensation expense primarily resulting from additional stock option award grants at higher fair values. In addition, we incurred increased personnel-related costs of$0.4 million due to headcount growth. - General and Administrative (“G&A”) Expenses: G&A expenses consist primarily of administrative employee-related expenses, legal and other professional fees, patent filing and maintenance fees, and insurance. These expenses for the three months ended March 31, 2021, were
$4.4 million , compared to$1.5 million for the same prior-year period. The increase of$2.9 million was primarily due to a$1.2 million increase in stock-based compensation expense primarily resulting from additional stock option award grants at higher fair values, an increase of$0.7 million in personnel-related costs due to headcount growth, an increase of$0.5 million of directors and officers liability insurance premium, and an increase of$0.3 million in professional service fees associated with increased accounting and compliance activities.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as myelodysplastic syndromes (“MDS”) and acute myeloid leukemia (“AML”). For more information, please visit ALX Oncology’s website at www.alxoncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include, but are not limited to, statements regarding ALX Oncology’s financial condition, results of operations and sufficiency of its cash and cash equivalents to fund its planned operations as well as statements about ALX Oncology’s clinical pipeline, including the timing of clinical trial initiations and data releases, and the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of ALX148. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Report on Form 10-K, filed with the SEC on March 18, 2021, and other documents ALX Oncology subsequently files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
ALX ONCOLOGY HOLDINGS INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| Related-party revenue | $ | — | $ | 655 | ||||
| Operating expenses: | ||||||||
| Research and development | 9,849 | 3,828 | ||||||
| General and administrative | 4,359 | 1,473 | ||||||
| Cost of services for related-party revenue | — | 596 | ||||||
| Total operating expenses | 14,208 | 5,897 | ||||||
| Loss from operations | (14,208 | ) | (5,242 | ) | ||||
| Interest expense | (3 | ) | (215 | ) | ||||
| Other income, net | 26 | 7 | ||||||
| Loss before income taxes | (14,185 | ) | (5,450 | ) | ||||
| Income tax provision | — | (4 | ) | |||||
| Net loss and comprehensive loss | (14,185 | ) | (5,454 | ) | ||||
| Cumulative dividends allocated to preferred stockholders | — | (1,983 | ) | |||||
| Net loss attributable to common stockholders | $ | (14,185 | ) | $ | (7,437 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.35 | ) | $ | (2.37 | ) | ||
| Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted | 40,055,435 | 3,143,159 | ||||||
Condensed Consolidated Balance Sheet Data
(unaudited)
(in thousands)
| March 31, 2021 | December 31, 2020 | |||||||
| Cash and cash equivalents | $ | 429,855 | $ | 434,219 | ||||
| Total assets | $ | 432,910 | $ | 436,054 | ||||
| Total liabilities | $ | 14,426 | $ | 6,209 | ||||
| Total stockholders’ equity | $ | 418,484 | $ | 429,845 | ||||
GAAP to Non-GAAP Reconciliation
(unaudited)
(in thousands)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| GAAP net loss attributable to common stockholders, as reported | $ | (14,185 | ) | $ | (7,437 | ) | ||
| Adjustments: | ||||||||
| Stock-based compensation expense | 1,800 | 151 | ||||||
| Accretion of term loan | — | 108 | ||||||
| Mark-to-market adjustment on financial instruments | — | 100 | ||||||
| Total adjustments | 1,800 | 359 | ||||||
| Non-GAAP net loss attributable to common stockholders | $ | (12,385 | ) | $ | (7,078 | ) | ||
Use of Non-GAAP Financial Measures
We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.
“Non-GAAP net loss attributable to common stockholders” is not based on any standardized methodology prescribed by GAAP and represent GAAP net loss adjusted to exclude (1) stock-based compensation expense, (2) accretion of term loan (interest expense related to ALX Oncology’s amortization of debt discount) and (3) mark-to-market adjustment on financial instruments (which include preferred stock warrants and derivatives). Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
FAQ
What were ALX Oncology's financial results for Q1 2021?
What is ALX148 and its current clinical status?
What are the R&D expenses reported by ALX Oncology for Q1 2021?
Is ALX Oncology's cash sufficient for future operations?
